@FierceMedDev: Teleflex says it's buying catheter firm Hotspur for $15M and selling off its ortho unit for $45M. Item | Follow @FierceMedDev
@MarkHFierce: St. Jude's Medical's Q2 earnings disappoint. Story | Follow @MarkHFierce
@DamianFierce: Steris is buying U.S. Endoscopy for $270M in cash. More | Follow @DamianFierce
> St. Jude Medical ($STJ) CEO Dan Starks told investors that the company is preparing to pay about $60 million next year as the 2.3% medical device tax seems inevitable. Report
> Greatbatch is planning to establish a medical device R&D center in Singapore, looking to move past manufacturing components and enter the Asian device market. Release
> Guided Therapeutics snagged a CE mark for LuViva, the company's non-invasive scanner that detects cervical diseases that can lead to cancer. More
> Boston Scientific ($BSX) is touting positive trial data for two spinal cord stimulation devices, the Infinion 16 lead and the Clik Anchor, designed to treat spinal pain. News
> Massachusetts, home to many devicemakers, has become something of a ground zero for the device tax debate, and Democratic Senate Candidate Elizabeth Warren is taking flak from the local GOP, which says she hasn't done enough to oppose the pending 2.3% charge. Article
> Crux Biomedical gained FDA clearance for its new inferior vena cava filter with bi-directional retrieval, a first advance of its kind. The product is designed to trap blood clots that can cause pulmonary embolisms among at-risk patients. Release
Biotech News
@FierceBiotech: Boehringer backs study of mobile diabetes care. Story | Follow @FierceBiotech
@JohnCFierce: Buzz: Big investors likely to back next wave of biotech buyouts. Report | Follow @JohnCFierce
@RyanMFierce: I sense a micro tech bubble forming in genomic data interpretation, annotation software. I see a new company in this space every month or so. | Follow @RyanMFierce
> GSK boosts stake in Amicus as PhIII Fabry data looms. Article
> FDA hits green light on Vivus weight drug Qnexa. News
> Amag preps sNDA after Feraheme clears PhIII hurdles. Item
Pharma News
@FiercePharma: Humira sales growth helped fuel Abbott's Q2 revenues. $2.3 billion. Good for spinoff if it continues. More | Follow @FiercePharma
> J&J ramping up OTC production as 'decree' work allows. Article
> As Abbott nears breakup, Humira keeps on truckin'. Report
> Can Vivus diet drug beat Arena's Belviq? More
> Lexapro sales tank by 81% as Icahn fires back at Forest Labs. Story
Drug Delivery News
> Ex-Sanofi exec joins Kala as President and CEO. Story
> Tekmira's technology delivers Alnylam Phase I RNAi results. Article
> Tea leaves could deliver prostate cancer treatment. More
> Microparticles deliver vaccines to the gut. Item
> NuPathe stock climbs on migraine patch resubmission. News
Biomarkers News
> The ethics of Alzheimer's risk testing. Report
> Genetic biomarkers tag antipsychotic weight gain. Article
> U.S. researchers gain $6.5 M grant to smoke out COPD markers. News
> Markers map slide into Alzheimer's. More
> Biomarkers could make multiple sclerosis diagnosis easier. Story
> DeCode, Genentech find gene mutation marks protection against Alzheimer's. Article
> Gold stars in ultrasensitive biomarker test. Item
And Finally... China's diagnostic imaging market should surpass $2.6 billion by 2016, Millennium Research Group estimates, as Chinese hospitals continue their licensing and installation of new PET/CT systems. Release